Connetics Extina development to resume in Q3
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Connetics plans to initiate a Phase III trial of Extina (ketoconazole 2% foam) in seborrheic dermatitis in the third quarter following discussions with FDA regarding a November 2004 "not approvable" letter, the firm says June 8. That timeline "should position Connetics to resubmit the NDA for Extina…by the end of 2006 with an anticipated review time of up to six months." The new trial is designed to demonstrate superiority to placebo foam. Extina was deemed not approvable Nov. 23, 2004 due to a lack of superiority to placebo foam in a previous Phase III trial; Connetics noted that non-inferiority to J&J's Nizoral (ketoconazole 2% cream) was demonstrated in that trial (1Pharmaceutical Approvals Monthly December 2004, p. 13)...
You may also be interested in...
Extina "Not Approvable" Decision Reflects Non-Superiority Over Placebo
Extina "not approvable" due to lack of superiority to placebo foam, Connetics says; the ketoconazole foam for seborrheic dermatitis did meet primary endpoint of non-inferiority to active comparator. Firm will decide whether to pursue approval or switch to other pipeline projects. An additional clinical trial would not require significant changes and would be quick to complete, company notes
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.